TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
CTEV

Claritev Corporation

Healthcare · Health Information Services

25.00$ -15.0% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

Claritev Corporation (CTEV) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 257 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement CTEV
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
252 207 224 255 255 276 288 298 298 290 250 241 237 238 243 244 235 233 230 232 231 242 246 247 245 257 995
45 52 148 74 40 44 45 47 47 50 53 54 55 59 61 61 60 61 61 57 60 61 62 78 180 234 554
207 155 76 181 215 232 244 252 251 240 197 187 182 179 182 183 174 172 170 175 171 181 184 169 65 23 440
22 36 174 124 27 39 37 49 30 39 31 32 30 33 37 36 35 35 38 53 51 53 48 48 58 55 209
120 135 275 221 133 142 139 142 134 142 161 801 135 144 142 143 661 696 508 216 161 164 174 160 58 55 447
88 20 -200 -40 82 90 104 110 117 98 36 -614 47 35 40 41 -486 -524 -338 -41 9.7 17 10 8.7 6.7 23 49
91 86 82 76 64 64 68 72 71 73 77 82 83 82 84 83 82 81 82 81 92 100 101 99 98 100 399
-3.3 -66 -289 -188 59 -56 98 34 58 20 9.0 -648 1.9 -46 -31 -32 -562 -604 -419 -186 -90 -83 -46 -107 -93 -77 -322
-0.7 -9.5 -1.1 -15 13 -8.8 20 9.6 14 6.5 -11 2.1 1.7 -9.8 -6.9 -0.4 -22 -28 -27 -48 -19 -20 24 -26 -19 -17 -39
-2.6 -56 -288 -173 46 -47 78 25 44 14 20 -650 0.2 -36 -24 -31 -540 -577 -391 -138 -71 -63 -70 -81 -74 -59 -283
188 121 -106 -10 225 112 268 209 233 197 190 -462 190 142 160 159 -371 -414 -227 4.9 113 129 167 105 117 202 591

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?